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BACKGROUND AND PURPOSE: The goal of thrombolytic therapy in patients with acute ischemic stroke
is early recanalization, but this may result in delayed reperfusion injury. The purpose of this study was
to evaluate the neuroprotective effect of agmatine in a transient ischemic cat model by using MR
perfusion imaging and histopathologic analyses.
METHOD: One-hour temporary occlusion of the left middle cerebral artery of cats was performed in the
control ischemia group (n  10), and 100 mg/kg of agmatine was intravenously injected immediately
after recanalization in the agmatine-treated group (n  15). MR imaging was performed at 1, 24, and
48 hours after recanalization, and the perfusion patterns were investigated. Terminal–deoxynucleotidyl
transferase mediated nick and end-labeling (TUNEL) and hematoxylin-eosin (H&E) stainings were
performed at the corresponding sections.
RESULTS: In the control ischemia group, the number of TUNEL-positive cells was significantly
increased in the areas with reperfusion hyperemia (P  .05). In the agmatine-treated group, no significant
increase in the number of TUNEL-positive cells was noted in the areas of reperfusion hyperemia. The
difference in the number of TUNEL-positive cells between the control ischemia and agmatine-treated group
in the areas of reperfusion hyperemia was significant (P  .05). The total number of TUNEL-positive cells
and the area of severe ischemic neuronal damage on H&E stain were also significantly attenuated in the
agmatine-treated cats compared with the control ischemia cats (P  .05).
CONCLUSION: Our results suggest that agmatine has neuroprotective effects against reperfusion
injury and ischemia.
Recently, the main emphasis in the management of hyper-acute ischemic stroke has been placed in the recanalization
of the occluded artery. Aggressive therapeutic trials have stud-
ied the effectiveness of intravenous, intra-arterial, mechanical,
or combined thrombolysis in the treatment of hyperacute ce-
rebral infarcts.1-4
In the case of recanalization in animals, reperfusion hyper-
emia usually occurs and is detected by perfusion-weighted im-
aging (PWI) or positron-emission tomography (PET). How-
ever, it is unclear whether this reperfusion hyperemia is
beneficial or detrimental to the reperfused tissue. In rats, res-
toration of cerebral perfusion pressure after a period of isch-
emia consistently resulted in amarked and variably prolonged
hyperperfusion, often followed by a phase of secondary hypo-
perfusion, which is generally associated with a poor tissue
prognosis.5-8 In ketamine-anesthetized cats, the degree of
postischemic hyperperfusion was strongly associated with the
leakage of Evans blue and intracerebral petechial hemor-
rhages.9 However, in baboons, transient ischemia (20 min-
utes) followed by reperfusion hyperemia was not associated
with alterations on CT and showed only minimal random
neuronal injury.10 Thus, reperfusion hyperemia can save the
ischemic tissue by rapid restoration of the cerebral blood flow,
but delayed reperfusion injury may occur because of the pres-
ence of oxidants or free radical damage.11 In this regard, an
effective neuroprotective agent that can prevent such potential
harm after recanalization of the occluded vessel can become a
valuable armamentarium for brain salvage.
Agmatine is a primary amine formed by the decarboxyl-
ation of L-arginine and is an endogenous clonidine-displacing
substance, synthesized in the mammalian brain.12 It is known
to be neuroprotective against glutamate-induced necrotic
neuronal cell death in vitro and also acts as a competitive nitric
oxide synthase (NOS) inhibitor, in which nitric oxide (NO)
has been known to cause either apoptosis or necrosis of
cells.13-16
The purpose of this study was to evaluate the neuroprotec-
tive effect of agmatine in a transient ischemic cat model by
using MR perfusion imaging and histopathologic analyses of
cellular outcomes.
Materials and Methods
Animal Preparation
The animal experiments were performed in accordance with a proto-
col approved by the Committee for the Care and Use of Laboratory
Animals. Part I of the study consisted of the control ischemia group
(n  10). In this part of the study, the control ischemia reperfusion
model was made in cats, and its effects were evaluated by using MR
perfusion images and histopathologic specimens. The results of the
control ischemia group have been published previously.17 In part II of
the study (n  15), the animals underwent the identical procedure
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except that agmatinewas added to evaluate its effect in the reperfusion
model.
In brief, cats of either sex weighing 3.5–4.0 kg were anesthetized
by using 5 mg/kg of ketamine chloride and 2 mg/kg xylazine hydro-
chloride. Rectal temperature wasmaintained at 37°C by a heating pad
during the operation. Oxygen saturation was maintained at 92%.
The left brachial vein and the right femoral artery were cannulated for
infusion of the fluid and physiologic monitoring. The left middle
cerebral artery (MCA) was exposed via a transorbital approach and
occluded by a microvascular clamp for a vessel size of 0.4–1.0 mm
(Acland clamp, S&TMicrolab AG, Rheinfall, Switzerland). One hour
after vascular clamping, the clips were released, and the craniotomy
site was sealed with bone wax. We injected 100 mg/kg of agmatine
(Sigma Chemical Co, St. Louis, Mo) mixed in 0.9% saline solution
intravenously immediately after reperfusion for the agmatine-treated
group of cats. In 2 additional normal control cats, only enucleation-
sphenoid craniotomy was performed, without the induction of tran-
sient cerebral ischemia.
Image Acquisition and Data Analysis
The animals were transferred to the MR imaging scanner (1.5T, In-
tera, Philips Medical Systems, Best, the Netherlands). The first MR
imaging was performed 1 hour after reperfusion followed by serial
MR imaging 24 and 48 hours after the first imaging session. We ob-
tained coronal section images perpendicular to a theoretic line drawn
from the anterior to the posterior commissure and transecting the
bilateral striatum,which corresponded to the histologic sections. PWI
(gradient-echo echo-planar imaging; TR/TE, 1500/40 msec; 128 
128 matrix) was performed after injection of a double dose of gado-
linium dimeglumine (Magnevist, Schering AG, Berlin, Germany).
Overall, 40 phase images were obtained for each section and pro-
cessed by commercially available postprocessing software (EasyVi-
sion, PhilipsMedical Systems), and the relative cerebral blood volume
(rCBV) was calculated.
To determine the evolution of the ischemic brain tissue in accor-
dance with the PWI findings, we investigated 5 different brain regions
in each cat. The 5 brain regions were the superior/inferior frontal gyri,
superior/inferior temporal gyri, and the striatum. The rCBV values
were measured in each region, and the results were divided into 4
groups according to the appearance of perfusion changes as follows;
normal perfusion (N), initial reperfusion hyperemia with late contin-
uous hyperperfusion or late normal perfusion (I), initial reperfusion
hyperemia and gradual depletion of rCBV (II), and persistent hypo-
perfusion throughout the experiment (III). The 1-hour and the 48-
hour PWIwere used as standards for determining early and late reper-
fusion patterns. The 24-hour PWI was used as an adjunct in
determining the trend in the perfusion pattern changes. Increased or
decreased rCBV of 20% compared with the contralateral normal side
was regarded as hyper- or hypoperfusion.
Pathologic Specimens
The sagittal localizer images from which the coronal PWI had been
acquired were used as reference for sectioning of the pathologic spec-
imen. Terminal–deoxynucleotidyl transferase mediated nick and
end-labeling (TUNEL)-stained, paraffin-embedded sections were
deparaffinized by washing them twice with xylene for 5 minutes. The
sections were then washed sequentially in 100%, 95%, and 75% eth-
anol before being incubated with 20 mg/mL of proteinase K (Sigma
Chemical Co) for 5minutes to strip the nuclear proteins. TUNELwas
accomplished by using the In Situ Cell Death Detection Kit (Roche,
Penzberg, Germany). After immersion in an equilibration buffer for
10 minutes, the sections were incubated with terminal–deoxynucle-
otidyl transferase (TdT) and deoxyuridine triphosphate (dUTP)-
digoxigenin in a humidified chamber at 37°C for 1 hour and then
incubated in a stop/wash buffer at 37°C for 30 minutes to stop the
reaction. The sections were then washed with phosphate-buffered
saline once before incubation in an antidigoxigenin–peroxidase solu-
tion for 30 minutes. They were colorized with diaminobenzidine-
H2O2 solution (Sigma Chemical Co, 0.2 mg/mL tetrachloride and
0.005% H2O2 in 50 mmol/L Tris-HCl buffer) and then counter-
stained with methyl green or hematoxylin. The control sections were
treated similarly but were incubated in the absence of TdT enzyme,
dUTP-digoxigenin, or antidigoxigenin antibody.
From the multiple pathologic slides that were produced from this
process, the slide that corresponded best with the MR imaging ana-
tomic landmarks was selected. TUNEL-positive cells were counted in
a blind fashion from10 rectangular areasmeasuring 150 000m2 and
averaged in each anatomic region as described previously by using
high-powered-field (200) lightmicroscopy.Hematoxylin and eosin
(H&E) staining was performed at the corresponding sections, and the
area of severe ischemic neuronal damage characterized by moderate-
to-severe neuronal shrinkage, increased eosinophilic neurons, nu-
clear basophilia, and nuclear pyknosis was assessed by using a com-
puter assisted image analysis system (MCID, Imaging Research Inc.,
St. Catherines, ON, Canada). The area of severe ischemic neuronal
damage was expressed as a percentage of the total area of the ipsilat-
eral neocortex, striatum, and hemisphere and corrected for the pres-
ence of edema.18
Statistical Analysis
Statistical analysis was performed by using 1-way analysis of variance
(ANOVA)with the Scheff e´ test to compare the differences among the
reperfusion types. Independent t and Kolmogorov-Smirnov tests
were performed to compare the differences between the control isch-
emia and agmatine-treated groups.
Results
Physiologic parameters, including body temperature, blood
pressure, and arterial oxygen saturation levels, of all cats were
within normal ranges and remained stable throughout the op-
eration and imaging procedures.
Reperfusion Pattern After Temporary Ischemia
Early reperfusion hyperemia (type I or II) was noted in all
cases of control ischemia and agmatine-treated cats. Themost
common reperfusion pattern was early hyperperfusion–late
normo-/hyperperfusion (type I, 43%, n  54/125). This pat-
tern of reperfusion was distributed evenly in the hemisphere
(Table).
Incidence of reperfusion types in the respective brain regions
SF IF ST IT Striatum Total (n125)
I 9 (5/4) 12 (6/6) 10 (4/6) 14 (4/10) 9 (4/5) 54 (23/31)
II 2 (0/2) 4 (1/3) 6 (4/2) 2 (1/1) 4 (1/3) 18 (7/11)
III 3 (0/3) 1 (0/1) 4 (1/3) 5 (3/2) 9 (4/5) 22 (8/14)
N 11 (5/6) 8 (3/5) 5 (1/4) 4 (2/2) 3 (1/2) 31 (12/19)
Note:—SF indicates superior frontal lobe; IF, inferior frontal lobe; ST, superior temporal
lobe; IT, inferior temporal lobe; I, initial reperfusion hyperemia with late continuous
hyperperfusion or late normal perfusion; II, initial reperfusion hyperemia and gradual
depletion of rCBV; III, persistent hypoperfusion; N, normal perfusion. Numbers in paren-
theses are related as follows: (Control ischemia group/agmatine-treated group).
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Early hyperperfusion–late hypoperfusion pattern (type II)
was the least commonly observed pattern of reperfusion (14%,
n  18/125). This pattern was most often observed in the
superior temporal gyrus (33%, n  6/18) but was also ob-
served in other MCA territories.
Early hypoperfusion–late hypoperfusion pattern (type III)
was noted in 18% (n 22/125) of the sectors. Nine (41%) of
the 22 sectors showing this pattern of reperfusionwere located
in the striatum.
Normal perfusion pattern (type N) was observed in 25%
(n  31/125) of the sectors, mostly in the frontal gyri (61%,
n 19/31).
Histopathologic Findings
TUNEL-Positive Cell Count
Themean number of total TUNEL-positive cells was higher in
the control ischemia cats compared with the agmatine-treated
cats (35.7 15.8 versus 17.4 34.8, P .05).
In the control-ischemia cats, a significant difference in the
number of TUNEL-positive cells was demonstrated between
the reperfusion types (1-wayANOVA test,P .05). The num-
ber of TUNEL-positive cells observed in the N-type reperfu-
sionwas 16.8 5.2.However, significantly increased TUNEL-
positive cell counts were demonstrated in the areas of type I
and II reperfusions, with counts of 39.5  13.4 and 43.6 
16.8, respectively. In the areas of type III reperfusion, TUNEL-
positivity was lower than the other types of reperfusion hyper-
emia, with cell counts of 23.3 7.0 (Scheff e´ test: N versus I,
P .05; N versus II, P .05; II versus III, P .05).
In the agmatine-treated cats, no statistically significant dif-
ference between the reperfusion types and the number of
TUNEL-positive cells was demonstrated (1-way ANOVA).
The number of TUNEL-positive cells observed in the N-type
reperfusion was 14.1  29.3. In the areas with reperfusion
hyperemia types I and II, the TUNEL-positive cell counts were
18.4 39.5 and 13.9 30.2, respectively. In the area of type III
reperfusion, TUNEL positivity was slightly higher than the
other types of reperfusion, with the cell count being 23.0 
37.5 (Fig 1).
In terms of the difference of TUNEL-positive cells between
the control ischemia and agmatine-treated groups in the re-
spective reperfusion types, the type I and II reperfusions in the
agmatine-treated group showed a significantly lower cell
count compared with the corresponding control ischemia
group reperfusion types (independent t test and Kolmogorov-
Smirnov test, P  .05). Types N and III reperfusions did not
show a significant difference in the number of TUNEL-posi-
tive cells between the control ischemia and agmatine treated
groups.
In the 2 normal control cats, no abnormal findings on MR
imaging were detected, and most parts of brain showed
TUNEL negativity, except for 1 cat that showed a few scattered
TUNEL-positive cells (10) in the temporal lobe.
H&E Stain
The area of ischemic neuronal damage on H&E stain, indi-
cated by the cells showing severe neuronal shrinkage, in-
creased nuclear basophilia, and pyknosis, measured 25.6 
10.9% of the ipsilateral hemisphere in the control-ischemia
group. The area of ischemic neuronal damage was signifi-
cantly attenuated in the agmatine-treated group, measuring
16.7 4.9% (P .05).
Discussion
The results of this study have shown the neuroprotective ef-
fects of agmatine against reperfusion injury and ischemia in a
transient ischemic cat model.
Histologically, the number of TUNEL-positive cells
showed significant attenuation in the areas of reperfusion hy-
peremia with the administration of agmatine. In addition to
the significant decrease of the total number of TUNEL-posi-
tive cells, the decrease of the area of ischemic neuronal damage
on H&E stain in the agmatine-treated group also reflects the
neuroprotective effect of agmatine.
Experimental studies have shown that restoration of cere-
bral blood flow after a period of ischemia consistently resulted
in a marked and prolonged hyperperfusion. This hyperperfu-
sion phase was often followed by a phase of secondary hypo-
perfusion generally associated with a poor tissue prognosis.5-8
By performing MR perfusion imaging for the evaluation of
reperfusion patterns in this study, we were able to assess the
various patterns of reperfusion with relatively high spatial
resolution. Areas of reperfusion hyperemia—type I (early
hyperperfusion–late normo-/hyperperfusion) and type II
(early hyperperfusion–late hypoperfusion)—showed signifi-
cant increases in the TUNEL-positive cell count in the control
ischemia group, compared with the regions of normal reper-
fusion (type N), indicating the induction of cellular injury by
reperfusion hyperemia. On the other hand, the TUNEL-posi-
tive cell count did not show any significant difference between
the areas of type I or II hyperemia and normal reperfusion in
the agmatine-treated group. Also, direct comparison of the
TUNEL-positive cell count between the control ischemia and
agmatine-treated groups in the type I and II hyperemic areas
showed significant attenuation of the TUNEL-positive cells by
agmatine.
Themajor causes of secondary brain damage after transient
ischemic stroke and reperfusion are a combination of pro-
cesses, including damage by excitotoxic amino acids, oxygen
free radicals, apoptosis, and inflammatory reactions.19 Gluta-
mate is a major excitatory neurotransmitter, and its toxicity
has been ascribed to excessive excitatory neurotransmission.
Ischemia causes massive efflux of glutamate into the extracel-
lular space of the brain, raising its concentration to the toxic
level. This induces intracellular Ca2 increase, which then ac-
tivates enzymes that cleave to structural or regulatory proteins
and the membrane lipids, eventually leading to cell destruc-
tion.20,21 Structural damage during reperfusion is also thought
to be a consequence of the excessive generation of oxygen free
radicals followed by lipid peroxidation. The changes in the
conformation of the free fatty acids resulting from lipid per-
oxidation alters the permeability and fluidity of themembrane
and compromises the functions of receptors, ion channels,
and other proteins.22 Peroxynitrite, formed by the reaction of
O2 with NO (produced by neuronal constitutive [nNOS or
iNOS]), is implicated as the lipid peroxidation–initiating rad-
ical species during reperfusion.23,24
Inflammatory reaction is also implicated as having a role in
reperfusion injury. The recruitment of neutrophils to the area
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of ischemia, the first step to inflammation, involves the coor-
dinated appearance of multiple adhesion molecules.19,25 Re-
cently, apoptosis has gained much attention as a mechanism
for secondary neuronal death after transient ischemia. By
demonstrating the nucleosomal ladders of DNA fragments in
transient ischemia and reperfusion models, previous reports
Fig 1. Agmatine-treated cat with type I and II reperfusion.
A, Persistent hyperperfusion is noted in the left frontal lobe (type I reperfusion, arrow). Initial hyperemia in the left striatum shows hypoperfusion on the last follow-up image (type II
reperfusion, arrowhead ). Notice the lack of signal-intensity changes on T2-weighted (T2WI) or diffusion-weighted images (DWI.). (B ) A few red-stained TUNEL-positive cells are seen in
all regions of the left hemisphere. ADC indicates apparent diffusion coefficient.
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have shown that cell death during ischemia is mainly necrotic,
whereas damage induced by reperfusion caused additional cell
death principally through apoptosis.26-28
The mechanism of neuroprotective effects of agmatine, as
shown in this study, can be attributed to its multimolecular
biologic actions.29 First, agmatine is known to inhibit the
(NMDA) subtype of glutamatergic receptors, thus impeding
the intracellular accumulation of Ca2.13,30,31 Second, agma-
tine can inhibit all isoforms of NOS, with the highest reported
activity as an irreversible inactivator of neuronal NOS, leading
to reduced production of the neuromodulator NO.14,16,32
Third, agmatine interferes with the intracellular signaling
pathways by inhibiting ADP–ribosylation of proteins, a pro-
cess implicated in neuronal injury after cerebral ischemia in
rats.33 These actions of agmatine can be postulated to coun-
teract both the necrotic and apoptotic processes of cell death
in this transient ischemia model.
Even though TUNEL staining has been accepted as a
method for histologic assay for detection of apoptosis, it can-
not always distinguish apoptotic and necrotic cells and some-
times falsely identifies cells in the process of DNA repair or
cells in the process of active gene transcription.34,35 Thus, de-
spite careful characterization of TUNEL staining to avoid in-
clusion of cells that demonstrated diffuse light staining, which
could be observedwith necrosis, the significant decrease in the
total TUNEL-positive cell count in the agmatine-treated
group in our study may include necrotic cells.36
Areas of type III reperfusion showing consistent hypoper-
fusion after recanalization failed to show a decrease in the
number of TUNEL-positive cells after agmatine treatment in
comparison with the control ischemia group. This type of
reperfusion may represent areas of nonrecanalization due to
persistent proximal occlusion or the “no-reflow phenome-
non,” inwhich the neuroprotective agentwas not able to reach
the ischemic tissue in effective concentrations. This no-reflow
phenomenon is known to be caused by amultiplicity of factors
such as increased blood viscosity, intravascular coagulation,
and microvascular occlusion by leukocytes.37
The number of TUNEL-positive cells in the agmatine-
treated groups showed a large variation. The main reason
seems to be that in a small number of cats, agmatine appeared
to be ineffective in neuroprotection. The TUNEL-positive cell
counts were very high in these cats despite agmatine infusion.
The reason for this is unclear, but we suspect that thismay also
be due to the no-reflow phenomenon in some instances, rela-
tively more severe damage during the 1-hour occlusion—per-
haps due to poor collateral circulation, or unknown mecha-
nisms of agmatine resistance in some cats.
Previous studies on the effects of exogenously applied ag-
matine have also shown its biologic activities in the brain.
Agmatine decreased the extent of neuronal loss and improved
the motor function after ischemic and traumatic spinal cord
injury in rats.29,38 The weight deficit of the ischemic hemi-
sphere was attenuated in hypoxic ischemic models in rat pups
by using agmatine doses of 50 and 100 mg/kg.39 The neuro-
protective effect of agmatine against delayed neuronal cell
death was also shown in the gerbil hippocampus after global
forebrain ischemia.40
The timing of intravenous administration of agmatine has
been selected to coincide with the onset of reperfusion in this
study.Many previous animal studies have shown the effective-
ness of agmatine when administered with the onset of reper-
fusion.29,38-40 This protocol is practical because it simulates
the actual clinical setting of hyperacute ischemic stroke and
recanalization therapy. However, a recent study has shown the
neuroprotective effects of agmatine when administered before
or during occlusion and even 2 hours postrecanalization, by
using in vivo strokemodels.16 Future studies with administra-
tion protocols reflecting such a time window of effects may
provide further evidence for the use of agmatine as a preven-
tive treatment in the high-risk group or as an adjunctive ther-
apeutic option in the extended time window.
The use of ketamine as an anesthetic in our study is a lim-
itation. Ketamine interacts with the phencyclidine binding
site, which is located in the NMDA receptor–associated ion
channel. It inhibits the influx of Na and Ca2 ions through
this channel, thus noncompetitively antagonizing the actions
of NMDA agonists and acting as a neuroprotective agent.41,42
Some animal studies have used inhalation anesthetics such as
halothane or isoflurane in conjunction with ketamine to re-
duce the neuroprotective effects.43,44 However, the design of
our study did not permit the use of inhalation agents because
of the lack of aMR imaging–compatible inhalation anesthetic
machinery. Our study used MR imaging to analyze the tem-
poral changes of reperfusion and correlated its outcome with
histologic findings. The advantage of MR imaging in terms of
spatial resolution is critical in assessing the variable patterns of
reperfusionwithin the brain of a small animal. Also, we believe
that the use of ketamine did not significantly influence the
outcome because identical anesthetic conditions were applied
to both the control ischemia and agmatine-treated groups.
In conclusion, the neuroprotective effects of agmatine
against reperfusion injury and ischemia have been demon-
strated in a transient ischemic cat model designed to simulate
the clinical situation of hyperacute ischemic stroke and its
treatment by recanalization. Further validation of agmatine as
a neuroprotective agent in terms of the drug administration
protocol, combined reperfusion therapy, and prolonged isch-
emia is warranted.
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